Navidea Biopharmaceuticals, Inc. reports developments tied to its biopharmaceutical platform, corporate status, and capital structure. The company focuses on precision immunodiagnostic agents and immunotherapeutics built around the Manocept platform, which targets the CD206 mannose receptor expressed on activated macrophages. Its disclosed programs include Tc99m tilmanocept and clinical work in rheumatoid arthritis, along with a stated focus on therapeutic assets.
Navidea news also covers Chapter 11, Subchapter V bankruptcy proceedings, OTC trading status, voluntary SEC deregistration actions, reverse stock split authority, Section 382 rights plan matters related to tax assets, litigation settlements, special stockholder meetings, and board changes. These updates place the company’s product-development strategy alongside recurring disclosure themes involving governance, financing, reporting obligations, and corporate restructuring.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.